Open Source Imaging Consortium (OSIC)
OSIC – a global, 501(c)(3), not-for-profit cooperative effort between academia, industry and patient advocacy groups – was created to enable rapid, open source advances in the fight against idiopathic pulmonary fibrosis (IPF), fibrosing interstitial lung diseases (ILDs), and other respiratory diseases, including emphysematous conditions.
OSIC brings together radiologists, clinicians, computational scientists, and industry competitors from around the world to advance digital imaging biomarkers for accurate imaging-based diagnosis, prognosis and prediction of response to therapy.
The partners work in pre-competitive areas for mutual benefit and, most importantly, the benefit of patients.
A First‑of‑its‑Kind, Global Data Repository for Interstitial Lung Diseases
OSIC has launched its highly-anticipated, data repository of anonymized HRCT scans and clinical information regarding interstitial lung diseases (ILDs). This first-of-its-kind database is the world’s largest and most diverse, with a plethora of real world clinical and imaging data that is both multi-ethnic and multi-center. Driven by global experts in pulmonology, radiology and artificial intelligence, the repository currently houses close to 1,500 anonymized and quality-controlled scans with accompanying data, and has an additional 5,000 in the quality control queue. It is on track to reach its goal of 15,000 anonymized scans, available to OSIC members, by first quarter 2022.
A call for the widespread adoption of QCT in routine clinical practice
OSIC is conducting a short, up-to-three question survey that will help shape our views as we develop our first white paper. We are seeking responses from clinicians and radiologists regarding their use of quantitative computed tomography (QCT) in routine clinical practice. As always, we value your expertise and support as we continue our mission to make rapid progress in the fight against IPF and other ILDs.